Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on February 24, 2021, covering events occurring on February 19, 2021, and the closing of an offering on February 23, 2021. The Company is a Delaware corporation headquartered in Menlo Park, CA, and its common stock and warrants trade on The NASDAQ Stock Market LLC under the symbols ATNF and ATNFW, respectively.
Key Financial Metrics and Capital Structure
- Offering Proceeds: The Company sold 2,564,000 shares of Common Stock and warrants to purchase an equal number of shares at a combined price of $4.55 per unit.
- Gross Proceeds: Approximately $11.7 million.
- Net Proceeds: Approximately $10.8 million after deducting placement agent fees (7%) and estimated offering expenses.
- Warrant Terms: Exercise price of $5.00 per share; immediately exercisable; 5-year term; subject to a 4.99% beneficial ownership limitation (increasable to 9.99% with consent).
- Debt Reduction: On February 4 and 5, 2021, holders converted $423,416.67 of principal and interest from convertible promissory notes into 128,730 shares of Common Stock at $3.29 per share.
- Remaining Debt: The outstanding balance of convertible promissory notes is approximately $316,000.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement and the subsequent closing of the equity offering. Key contractual obligations include:
- Registration Rights: The Company must file a registration statement by April 24, 2021, to register the resale of the new shares and warrant shares, with effectiveness targeted by June 23, 2021.
- Issuance Restrictions: The Company is restricted from issuing new equity or filing new registration statements for 30 days after the registration statement becomes effective or 30 days after Rule 144 eligibility, whichever is earlier.
- Lock-Up Agreements: Directors and executive officers are locked up from selling shares until the earlier of 60 days after the registration statement effectiveness or November 6, 2021.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking financial guidance, revenue projections, or specific management commentary regarding future operational performance. The primary focus is the successful capital raise to fund operations. Risks associated with the transaction include the dilution of existing shareholders and the Company's obligation to file registration statements within strict deadlines. The offering was conducted in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the final closing date of the offering (February 23, 2021) and the actual net proceeds received.
- Confirm the filing date and effectiveness status of the registration statement required by the Registration Rights Agreement (deadline: April 24, 2021).
- Review the full text of the Warrant agreement (Exhibit 4.1) for specific anti-dilution provisions and exercise limitations.
- Monitor the Company's cash burn rate to assess the runway provided by the $10.8 million net proceeds.
- Check for any subsequent filings regarding the conversion of the remaining $316,000 in convertible notes.